Korro Bio (NASDAQ:KRRO - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($2.60) per share and revenue of $0.13 million for the quarter.
Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($2.49) EPS for the quarter, beating analysts' consensus estimates of ($2.60) by $0.11. The firm had revenue of $2.55 million for the quarter, compared to analysts' expectations of $0.13 million. On average, analysts expect Korro Bio to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.
Korro Bio Stock Performance
NASDAQ:KRRO traded up $0.16 during trading hours on Friday, hitting $15.56. 33,917 shares of the company's stock traded hands, compared to its average volume of 97,926. The stock's fifty day moving average price is $17.78 and its two-hundred day moving average price is $34.32. The firm has a market cap of $146.12 million, a P/E ratio of -1.65 and a beta of 2.66. Korro Bio has a twelve month low of $11.13 and a twelve month high of $98.00.
Analysts Set New Price Targets
A number of equities analysts have commented on the company. Chardan Capital began coverage on Korro Bio in a research note on Wednesday, April 16th. They issued a "buy" rating and a $25.00 price objective on the stock. Royal Bank of Canada dropped their price objective on shares of Korro Bio from $105.00 to $95.00 and set an "outperform" rating for the company in a research report on Wednesday, March 19th. Cantor Fitzgerald upgraded Korro Bio to a "strong-buy" rating in a report on Tuesday, April 29th. Finally, HC Wainwright reduced their target price on shares of Korro Bio from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Thursday. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $112.75.
Get Our Latest Report on KRRO
About Korro Bio
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Featured Articles
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
